title: Long-term management of orbital and systemic reactive lymphoid hyperplasia with rituximab.
abstract: Rituximab, a monoclonal antibody to the B cell marker CD20, is becoming increasingly popular in the treatment of various orbital disorders. In this university-based interventional case series, we describe two patients with bilateral orbital and extra-orbital reactive lymphoid hyperplasia (RLH) treated with rituximab. Initially both had favorable responses; but roughly a year later recurrent disease necessitated maintenance therapy in both cases. Both again responded to additional courses of rituximab. Although recalcitrant disease may persist after treatment, rituxmab may play a role in the management of RLH with widespread involvement.
authors.affiliation: Department of Ophthalmology, University of California-San Francisco, San Francisco, California, USA.
authors.forename: Aiyin
authors.initials: A
authors.lastname: Chen
authors.forename: Thomas N
authors.initials: TN
authors.lastname: Hwang
authors.forename: Laura T
authors.initials: LT
authors.lastname: Phan
authors.forename: Timothy J
authors.initials: TJ
authors.lastname: McCulley
authors.forename: Michael K
authors.initials: MK
authors.lastname: Yoon
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018951:Antigens, CD20; D001706:Biopsy; D003937:Diagnosis, Differential; D005500:Follow-Up Studies; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009916:Orbital Diseases / Q000175:diagnosis / Q000188:drug therapy*; D019310:Pseudolymphoma / Q000175:diagnosis / Q000188:drug therapy*; D000069283:Rituximab; D013997:Time Factors
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D007155:Immunologic Factors; D000069283:Rituximab